AbbVie : Phase 3 Study Of Skyrizi In Crohn's Disease Meets All Primary And Secondary Endpoints
16/10 03:51
(RTTNews) - AbbVie (ABBV) presented positive results from the head-to-head Phase 3 SEQUENCE study that evaluated the efficacy and safety of risankizumab (Skyrizi, 600 mg intravenous [IV] at week 0, 4 and 8 and 360 mg subcutaneous [SC] starting at week 12 and every 8 weeks thereaf...